ArticleArchiv der Pharmazie2026
Synergistic Cytotoxicity of Cafestol and Kahweol With Doxorubicin in Breast Cancer Cells Involves TNF‑α Targeting and NF‑κB Downregulation.
Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Breast cancer (BC) is the most common cancer in women worldwide. Natural compounds have been studied to improve chemotherapy efficiency. Cafestol and kahweol (C&K) are diterpenes from coffee lipid fraction, with potential anticancer activity, whose effects and association with chemotherapeutic drug doxorubicin in BC cells are still unknown. Here, we evaluated the synergistic cytotoxic effects of the C&K with doxorubicin and their molecular mechanisms in BC cells. Cell viability was assessed by the MTT assay. Flow cytometry was used to analyze apoptosis, cell cycle, and NF-κB levels. The microarray assay was performed to identify altered signaling pathways, and molecular docking was utilized to predict the interaction between C&K and TNF-α. In addition, TCGA data were explored to evaluate the clinical association between the expression of C&K-regulated genes and TNF-α/NF-κB pathway genes. C&K was cytotoxic and increased the doxorubicin cytotoxicity, augmented the sub-G0/G1 phase, downregulated TNF-α/NF-κB pathway, decreased NF-κB protein levels, and showed affinity for TNF-α by molecular docking. Moreover, considering the C&K-modulated genes, BLOC1S1 acted as a protective factor for BC, and these genes were negatively correlated with TNF-α/NF-κB genes. Our data suggest that C&K have cytotoxic properties by inhibiting TNF-α/NF-κB pathway and interacting synergistically with doxorubicin in BC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.